Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases

Journal of Cellular and Molecular Medicine

Volumn 6, Issue 3, 2002, Pages 357-376

  Bodolay, Edit ^a   Koch, Alisa E ^b,c   Kim, Joon ^b   Szegedi, Gyula ^a   Szekanecz, Zoltan ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b NORTHWESTERN UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Chemokine; Chemokine receptor; Dermatomyositis; Mixed connective tissue disease; Polymyositis; Rheumatoid arthritis; Sj gren's syndrome; Systemic lupus erythematosus; Systemic sclerosis; Vasculitis

Indexed keywords

ANGIOGENESIS INHIBITOR; CHEMOKINE; CHEMOKINE RECEPTOR; GROWTH PROMOTOR;

AUTOIMMUNE DISEASE; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS;

ANGIOGENESIS INHIBITORS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CHEMOKINES; GROWTH SUBSTANCES; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CHEMOKINE;

EID: 0036652203     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2002.tb00514.x     Document Type: Review

References (122)

1. Brenchley P.E., Angiogenesis in inflammatory joint disease: a target for therapeutic intervention [editorial]. Clin. Exp. Immunol., 121: 426, 2000
2. Walsh D.A., Angiogenesis and arthritis. Rheumatology Oxford, 38: 103, 1999
3. Paleolog E.M., Fava R.A., Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies. Springer Semin. Immunopathol, 20: 73, 1998
4. Szekanecz Z., Koch A.E., Angiogenesis in rheumatoid arthritis. In: Rubanyi G.M., ed. Angiogenesis in health and disease. Marcel Dekker, New York, Basel; 2000, pp 429-450
5. Szekanecz Z., Szegedi G., Koch A.E., Angiogenesis in rheumatoid arthritis. J. Invest. Med. 46: 27, 1998
6. Koch A.E., Angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum, 41: 951, 1998
7. Colville-Nash P.R., Scott D.L., Angiogenesis in rheumatoid arthritis: pathogenic and therapeutic implications. Ann. Rheum. Dis, 51: 919, 1992.
8. Szekanecz Z., Halloran M.M., Haskell C.J., Shah M.R., Polverini P.J., Koch A.E., Mediators of angiogenesis: the role of cellular adhesion molecules. Trends Glycosci. Glycotechnol., (TIGG) 58: 73, 1999
9. Szekanecz Z., Koch A.E., Chemokines and angiogenesis. Curr. Opin. Rheumatol., 13: 202, 2001
10. Walchner M., Meurer M., Plewig G., Messer G., Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int. J. Dermatol, 39: 383, 2000
11. Gavino E.S., Furst D.E., Recombinant relaxin: a review of pharmacology and potential therapeutic use. BioDrugs, 15: 609, 2001
12. Hebbar M., Peyrat J.P., Hornez L., Hatron P.Y., Hachulla E., Devulder B., Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum, 43: 889, 2000
13. Ribatti D., Cantatore F.P., Vacca A., D'Amore M., Ria R., Roncali L., Pipitone V., Systemic sclerosis stimulates angiogenesis in the chick embryo chorioallantoic membrane. Clin. Rheumatol, 17: 115, 1998
14. Koch A.E., Litvak M.A., Burrows J.C., Polverini P.J., Decreased monocyte-mediated angiogenesis in scleroderma. Clin. Immunol. Immunopathol, 64: 153, 1992
15. Brahn E., Lehman T.J., Peacock D.J., Tang C., Banquerigo M.L., Suppression of coronary vasculitis in a murine model of Kawasaki disease using an angiogenesis inhibitor. Clin. Immunol, 90: 147, 1999
16. Terai M., Yasukawa K., Narumoto S., Tateno S., Oana S., Kohno Y., Vascular endothelial growth factor in acute Kawasaki disease. Am. J. Cardiol, 83: 337, 1999
17. Csernok E., Szymkowiak C.H., Mistry N., Daha M.R., Gross W.L., Kekow J., Transforming growth factor-β (TGF-β) expression and interaction with proteinase 3 (PR3) in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Clin. Exp. Immunol, 105: 104, 1996
18. Cid M.C., Grant D.S., Hoffman G.S., Auerbach R., Fauci A.S., Kleinman H.K., Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J. Clin. Invest, 91: 977, 1993
19. Folkman J., Angiogenesis - retrospect and outlook. EXS, 59: 4, 1991
20. Jackson C.J., Jenkins K., Schrieber L., Possible mechanisms of type I collagen-induced vascular tube formation. EXS, 59: 198, 1992
21. Koch A.E., Halloran M.M., Haskell C.J., Shah M.R., Polverini P.J. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature, 376: 517, 1995
22. Koch A.E., Polverini P.J., Kunkel S.L., Harlow L.A., DiPietro L.A., Elner V.M., Elner S.G, Strieter, R.M., Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science, 258: 1798, 1992
23. Grant D.S., Kleinman H.K., Goldberg I.D., Bhargava M.M., Nickoloff B.J., Kinsella J.L., Polverini P.J., Rosen E.M., Scatter factor induces blood vessel formation in vivo. Proc. Natl. Acad. Sci, USA, 90: 1937, 1993
24. Hernandez G.L., Volpert O.V., Iniguez M.A., Lorenzo E., Martinez-Martinez S., Grau R., Fresno M., Redondo J.M., Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J. Exp. Med., 193: 607, 2001
25. Mason J.C., Lidington E.A., Yarwood H., Lublin D.M., Haskard, D.O., Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthritis Rheum., 44: 138, 2001
26. Peichev M., Naiyer A.J., Pereira D., Zhu Z., Lane W.J., Williams M., Oz M.C., Hicklin D.J., Witte L., Moore M.A., Rafii S., Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood, 95: 952, 2000
27. Koch A.E., Harlow L.A., Haines G.K., Amento E.P., Unemori E.N., Wong W.L., Pope R.M., Ferrara N., Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol., 152: 4149, 1994
28. Sato N., Beitz J.G., Kato J., Yamamoto M., Clark J.W., Calabresi P., Frackelton A.R. Jr., Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am. J. Pathol. 142: 1119, 1993
29. Angiolillo A.L., Kanegane H., Sgadari C., Reaman G.H., Tosato G., Interleukin-15 promotes angiogenesis in vivo. Biochem. Biophys. Res. Commun., 233: 231, 1997
30. Halloran M.M., Carley W.W., Polverini P.J., Haskell C.J., Phan S., Anderson B.J., Woods J.M., Campbell P.L., Volin M.V., Backer A.E., Koch A.E., Ley/H: an endothelial-selective, cytokine-inducible, angiogenic mediator. J. Immunol., 164: 4868, 2000
31. Neidhart M., Wehrli R., Bruhlmann P., Michel B.A., Gay R.E., Gay S., Synovial fluid CD146 (MUC18), a marker for synovial membrane angiogenesis in rheumatoid arthritis. Arthritis Rheum., 42: 622, 1999
32. Vankemmelbeke M.N., Holen I., Wilson A.G., Ilic M.Z., Handley C.J., Keiner GS., Clark M., Liu C., Maki R.A., Burnett D., Buttle D.J., Expression and activity of ADAMTS-5 in synovium. Eur. J. Biochem., 268: 1259, 2001
33. Leahy K.M., Koki A.T., Masferrer J.L. Role of cyclooxygenases in angiogenesis. Curr. Med. Chem., 7: 1163, 2000
34. Neidhart M., Gay R.E., Gay S., Prolactin and prolactin-like polypeptides in rheumatoid arthritis. Biomed. Pharmacother., 53: 218, 1999
35. Auerbach W., Auerbach R., Angiogenesis inhibition: a review. Pharmac. Ther., 63: 265, 1994
36. Nagashima M., Asano G., Yoshino S., Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J. Rheumatol., 27: 2339, 2000
37. Calabrese L., Fleischer A.B., Thalidomide: current and potential clinical applications. Am. J. Med., 108: 487, 2000
38. Fishman S.J., Feins N.R., D'Amoto R.J., Folkman J., Thalidomide for Crohn's disease. Gastroenterology, 119: 596, 2000
39. Szekanecz Z., Haines G.K., Lin T.R., Harlow L.A., Goerdt S., Rayan G., Koch A.E., Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum., 37: 221, 1994
40. Johnson B., Haines G.K., Harlow L.A., Koch A.E., Adhesion molecule expression in human synovial tissues. Arthritis Rheum., 36: 137, 1993
41. Koch A.E., Turkiewicz W., Harlow L.A., Pope R.M., Soluble E-selectin in arthritis. Clin. Immunol. Immunopathol., 69: 29, 1993
42. Wellicome S.M., Kapahi P., Mason J.C., Lebranchu Y., Yarwood H., Haskard D.O., Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic Lupus erythematosus. Clin. Exp. Immunol., 92: 412, 1993
43. Szekanecz Z., Strieter R.M., Kunkel S.L., Koch A.E., Chemokines in rheumatoid arthritis. Springer Semin. Immunopathol., 20: 115, 1998
44. Koch A.E., Kunkel S.L., Strieter R.M., Chemokines in arthritis. In: Koch A.,E., Strieter R.M., eds., Chemokines in disease. RG Landes Company, Austin. 1996, pp 103-116
45. Harris E.D., Rheumatoid arthritis: pathophysiology and implications for therapy. N. Engl. J. Med., 332: 1277, 1990
46. Bazan J.F., Bacon K.B., Hardiman G., Wang W., Soo K., Rossi D., Greaves D.R., Zlotnik A., Schall T.J., A new class of membrane bound chemokine with a CX3C motif. Nature, 385: 640, 1997
47. Mackay C.R., Chemokines: what chemokine is that ? Curr. Biol., 7: R384, 1997
48. Taub D.D., C-C chemokines - an overview. In: Koch A.E., Strieter R.M., eds., Chemokines in disease, RG Landes Company, Austin, 1996, pp. 27-54
49. Walz A., Kunkel S.L., Strieter R.M., C-X-C chemokines - an overview. In: Koch A.,E., Strieter R.M., eds., Chemokines in disease. RG Landes Company, Austin. 1996, pp 1-25
50. Zlotnik A., Yoshie O., Chemokines: a new classification system and their role in immunity. Immunity, 12: 121, 2000
51. Wooley P.H., Schaefer C., Whalen J.D., Dutcher J.A., Counts D.F., A peptide sequence from platelet factor 4 (CT-112) is effective in the treatment of type II collagen induced arthritis in mice. J. Rheumatol., 24: 890, 1997
52. Strieter R.M., Polverini P.J., Kunkel S.L., Arenberg D.A., Burdick M.D., Kasper J., Dzuiba J., Van Damme J., Walz A., Marriott D., Chan S-Y., Roczniak S., Shanafelt A.B., The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem., 270: 27348, 1995
53. Strieter R.M., Kunkel S.L., Shanafelt A.B. The role of C-X-C chemokines in the regulation of angiogenesis. In: Koch A.E., Strieter R.M., eds. Chemokines in disease, RG Landes Company: Austin, 1996, pp 195-209
54. Moore B.B., Keane M.P., Addison C.L., Arenberg D.A., Strieter R.M., CXC chemokine modulation of angiogenesis: the importance of balance between angiogenic and angiostatic members of the family. J. Invest. Med., 46: 113, 1998
55. Hosaka S., Akahoshi T., Wada C., Kondo H., Expression of the chemokine superfamily in rheumatoid arthritis. Clin. Exp. Immunol., 97: 451, 1994
56. Koch A.E., Kunkel S.L., Harlow L.A., Johnson B., Evanoff H.L., Haines G.K., Burdick M.D., Pope R.M., Strieter R.M., Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J. Clin. Invest., 90: 772, 1992
57. Koch A.E., Kunkel S.L., Harlow L.A., Mazarakis D.D., Haines G.K., Burdick M.D., Strieter R.M., Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J. Clin. Invest., 94: 1012, 1994
58. Rathanaswami P., Hachicha M., Sadick M., Schall T.J., McColl S.R., Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J. Biol. Chem., 268: 5834, 1993
59. Ruth J.H., Volin M.V., Haines III G.K., Woodruff, D.C., Katschke K.J. Jr, Woods J.M., Park C.C., Morel J.C., Koch A.E., Fractalkine, a novel chemokine in rheumatoid arthritis and rat adjuvant-induced arthritis. Arthritis Rheum., 44: 1568, 2001
60. Borthwick N.J., Akbar A.N., MacCormac L.P., Lowdell M., Craigen J.L., Hassan I., Grundy J.E., Salmon M., Yong K., Selective migration of highly differentiated primed T cells, defined by low expression of CD45RB, across human umbilical vein endothelial cells: effects of viral infection on transmigration. Immunology, 90: 272, 1997
61. Loetscher P., Uguccioni M., Bordoli L., Baggiolini M., Moser B., Chizzolini C., Dayer J.M., CCR5 is characteristic of Th1 lymphocytes. Nature, 391: 344, 1998
62. Schonbeck U., Brandt E., Petersen F., Flad H.D., Loppnow H., IL-8 specifically binds to endothelial but not to smooth muscle cells. J. Immunol., 154: 2375, 1995
63. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., Oppenheim J.J., Murphy W.J., Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood, 96: 34, 2000
64. Addison C.L., Daniel T.O., Burdick M.D., Liu H., Ehlert J.E., Xue Y.Y., Buechi L., Walz A., Richmond A., Strieter R.M., The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J. Immunol, 165: 5269, 2000
65. Hogan M., Sherry B., Ritchlin C., Fabre M., Winchester R., Cerami A., Bucala R., Differential expression of the small inducible cytokines groa and grob by synovial fibroblasts in chronic arthritis: possible role in growth regulation. Cytokine, 6: 61, 1994
66. Koch A.E., Kunkel S.L., Burrows J.C., Evanoff H.L., Haines G.K., Pope K.M., Strieter R.M., Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J. Immunol., 147: 2187, 1991
67. Endo H., Akahoshi T., Takagishi K., Kashiwazaki S., Matsushima K., Elevation of interleukin-8 (IL-8) levels in joint fluids of patients with rheumatoid arthritis and the induction by IL-8 of leukocyte infiltration and synovitis in rabbit joints. Lymphokine Cytokine Res., 10: 245, 1991
68. Koch A.E., Volin M.V., Woods J.M., Kunkel S.L., Connors M.A., Harlow L.A., Woodruff D.C., Burdick M.D., Strieter R.M., Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide-78 in the rheumatoid joint. Arthritis Rheum., 44: 31, 2001
69. Kraan M.C., Patel D.D., Haringman J.J., Smith M.D., Weedon H., Ahern M.J., Breedveld F.C., Tak P.P., The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Res., 3: 65, 2001
70. De Gendt C.M., De Clerck L.S., Bridts C.H., Van Osselaer N., Stevens W.J., Relationship between interleukin-8 and neutrophil adhesion molecules in rheumatoid arthritis. Rheumatol. Int., 16: 169, 1996
71. Walz A., Burgener R., Car B., Baggiolini M., Kunkel S.L., Strieter R.M., Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J. Exp. Med., 174: 1355, 1991
72. Halloran M.M., Woods J.M., Strieter R.M., Szekanecz Z., Volin M.V., Hosaka S., Haines G.K. III, Kunkel S.L., Burdick M.D., Walz A., Koch A.E., The role of an epithelial neutrophil-activating peptide-78-like protein in rat adjuvant-induced arthritis. J. Immunol, 162: 7492, 1999
73. Koch A.E., Kunkel S.L., Shah M.R., Hosaka S., Halloran M.M., Haines G.K., Burdick M.D., Pope R.M., Strieter R.M., Growth related gene product alpha: A chemotactic cytokine for neutrophils in rheumatoid arthritis. J. Immunol., 155: 3660, 1995
74. Castor C.W., Andrews P.C., Swartz R.D., et al., The origin, variety, distribution, and biologic fate of connective tissue activating peptide-III isoforms: characteristics in patients with rheumatic, renal, and arterial disease. Arthritis Rheum., 36: 1142, 1993
75. Castor C.W., Smith E.M., Hossler P.A., Bignall M.C., Aaron B.P., Detection of connective tissue activating peptide-III isoforms in synovium from osteoarthritis and rheumatoid arthritis patients: patterns of interaction with other synovial cytokines in cell culture. Arthritis Rheum., 35: 783, 1993
76. Narumi S., Tominaga Y., Tamaru M., Expression of IFN-inducible protein-10 in chronic hepatitis. J. Immunol., 158: 5536, 1997
77. Patel D.D., Zachariah J.P., Whichard L.P., CXCR3 and CCR5 ligands in the rheumatoid arthritis synovium. Clin. Immunol., 98: 39, 2001
78. Buckley C.D., Amft N., Bradfield P.F., Pilling D., Ross E., Arenzana-Seisdedos F., Amara A., Curnow S.J., Lord J.M., Scheel-Toellner D., Salmon M., Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J. Immunol., 165: 3423, 2000
79. Nanki T., Hayashida K., El-Gabalawy H.S., Suson S., Shi K., Girschick H.J., Yavuz S., Lipsky P.E., Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J. Immunol., 165: 6590, 2000
80. Salcedo R., Wasserman K., Young H.A., Grimm M.C., Howard O.M., Anver M.R., Kleinman H.K., Murphy W.J., Oppenheim J.J., Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1 alpha. Am. J. Pathol., 154: 1125, 1999
81. Akahoshi T., Wada C., Endo H., Hirota K., Hosaka S., Takagishi K., Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. Arthritis Rheum., 36: 762, 1993
82. Koch A.E., Kunkel S.L., Harlow L.A., Mazarakis D.D., Haines G.K., Burdick M.D., Pope R.M., Strieter R.M., Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J. Clin. Invest., 93: 921, 1994
83. Matsui T., Akahoshi T., Namai R., Hashimoto A., Kurihara Y., Rana M., Nishimura A., Endo H., Kitasato H., Kawai S., Takagishi K., Hondo H., Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis. Clin. Exp. Immunol., 125: 155, 2001
84. Ruth J.H., Morel J.C.M., Park C.C., Koch A.E., MIP-3a expression in the rheumatoid joint. Arthritis Rheum., 43 (9 Suppl): S78, 2000
85. Schall T.J., Bacon K., Toy K.J., Goeddel D.V., Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature, 347: 669, 1990
86. Robinson E., Keystone E.C., Schall T.J., Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells. Clin. Exp. Immunol., 101: 398, 1995
87. Volin M.V., Woods J.M., Amin M.A., Connors M.A., Harlow L.A., Koch A.E., Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis, Am. J. Pathol., 159: 1521, 2001
88. Wedderburn L.R., Robinson N., Patel A., Varsani H., Woo P., Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum., 43: 765, 2001
89. Katschke K.J. jr, Rottman J.B., Ruth J.H., Qin S., Wu L., LaRosa G., Ponath P., Park C.C., Pope R.M., Koch A.E., Differential expression of chemokine receptors on peripheral blood, synovial fluid and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum., 44: 1022, 2001
90. Narumi S., Takeuchi T., Kobayashi Y., Konishi K., Serum levels of IFN-inducible protein-10 relating to the activity of systemic Lupus erythematosus. Cytokine, 12: 1561, 2000
91. Kaneko H., Ogasawara H., Naito T., Akimoto H., Lee S., Hishikawa T., Sekigawa I., Tokano Y., Takasaki Y., Hirose S.I., Hashimoto H., Circulating levels of beta-chemokines in systemic Lupus erythematosus. J. Rheumatol., 26: 568, 1999
92. Rus V., Atamas S.P., Shustova V., Luzina I.G., Selaru F., Magder L.S., Via C.S., Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from Lupus patients by cDNA array. Clin. Immunol., 102: 283, 2002
93. Hase K., Tani K., Shimizu T., Ohmoto Y., Matsushima K., Sone S., Increased CCR4 expression in active systemic Lupus erythematosus. J. Leukocyte Biol., 70: 749, 2001
94. Yamada M., Yagita H., Inoue H., Takanashi T., Matsuda H., Munechika E., Kanamaru Y., Shirato I., Tomino Y., Matsushima K., Okumura K., Hashimoto H., Selective accumulation of CCR4+ T lymphocytes into renal tissue of patients with Lupus nephritis. Arthritis Rheum., 46: 735, 2002
95. Galindo M., Santiago B., Rivero M., Rullas J., Alcami J., Pablos J.L., Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum., 44: 1382, 2001
96. Yamamoto T., Hartmann K., Eckes B., Krieg T., Role of stem cell factor and monocyte chemoattractant protein-1 in the interaction between fibroblasts and mast cells in fibrosis. J. Dermatol. Sci., 26: 106, 2001
97. Renzoni E., Lympany P., Sestini P., Pantelidis P., Wells A., Black C., Welsh K., Bunn C., Knight C., Foley P., du Bois R.M., Distribution of novel polymorphisms of the interleukin 8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum., 43: 1633, 2000
98. Cuello C., Palladinetti P., tedla N., Di Girolamo N., Lloyd A.R., McCluskey P.J., Wakefield D., Chemokine expression and leucocyte infiltration in Sjögren's syndrome. Br. J. Rheumatol., 37: 779, 1998
99. Xanthou G., Polihronis M., Tzioufas A.G., Paikos S., Sideras P., Moutsopoulos H.M., "Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjögren's syndrome patients. Arthritis Rheum., 44: 408, 2001
100. Amft N., Curnow S.J., Scheel-Toellner D., devadas A., Oates J., Crocker J., Hamburger J., Ainsworth J., Mathews J., Salmon M., Bowman S.J., Buckley C.D., Ectopic expression of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjögren's syndrome. Arthritis Rheum., 44: 2633, 2001
101. Amft N., Bowman S.J., Chemokines and cell trafficking in Sjögren's syndrome. Scand. J. Immunol., 54: 62, 2001
102. Salomonsson S., Larsson P., Tengner P., Mellquist E., Hjelmstrom P., Wahren-Herlenius M., Expression of B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sjögren's syndrome. Scand. J. Immunol., 55: 336, 2002
103. Mustafa W., Sharafeldin A., Diab A., Huang Y.M., Bing H., Zhu J., Link H., Frithiof L., Klinge B., Coordinate up-regulation of the beta-chemokine subfamily in autoimmune sialoadenitis of MRL/lpr mice. Scand. J. Immunol., 48: 623, 1998
104. Liprandi A., Bartoli C., Figarella-Branger D., Pellissier J.F., Lepidi H., Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies. Acta Neuropathol. (Berl.), 97: 642, 1999
105. Confalonieri P., Bernasconi P., Megna P., Galbiati S., Cornelio F., Mantegazza R., Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J. Neuropathol. Exp. Neurol., 59: 164, 2000
106. Adams E.M., Kirkley J., Eidelman G., Dohlman J., Plotz P.H., The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc. Assoc. Am. Physicians, 109: 275, 1997
107. Balding C.E., Howie A.J., Drake-Lee A.B., savage C.O., Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. Clin. Exp. Immunol., 125: 332, 2001
108. Haley K.J., Lilly C.M., Yang J.H., Feng Y., Kennedy S.P., Turi T.G., Thompson J.F., Sukhova G.H., Libby P., Lee R.T., Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation, 102: 2185, 2000
109. Casselman B.L., Kilgore K.S., Miller B.F., Warren J.S., Antibodies to neutrophil cytoplasmic antigens induce monocyte chemoattractant protein-1 secretion from human monocytes. J. Lab. Clin. Med., 126: 495, 1995
110. Keane M.P., Strieter R.M., The role of CXC chemokines in the regulation of angiogenesis. Chem. Immunol., 72: 86, 1999
111. Rinaldi N., Schwarz-Eywill M., Weis D., Leppelmann-Jansen P., Lukoschek M., Keilholz U., Barth T.F., Increased expression of integrins on fibroblast-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins. Ann. Rheum. Dis., 56: 45, 1991
112. Vicari A.P., Ait-Yahia S., Chemin K., Mueller A., Zlotnik A., Caux C., Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol., 165: 1992, 2000
113. Volin M.V., Harlow L.A., Woods J.M., Campbell P.L., Amin M.A., Tokuhira M., Koch A.E., Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor induced endothelial cell chemotaxis. Arthritis Rheum. 42, 1927, 1999.
114. th Edition, WB Saunders, Philadelphia, 2001, p 899
115. Lin Y.S., Nguyen C., Mendoza J.L., Escandon E., Fei D., Meng Y.G., Modi N.B. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther., 288: 371, 1999
116. Nicosia R.F., Bonanno E., Inhibition of angiogenesis in vitro by Arg-Gly-Asp-containing synthetic peptide. Am. J. Pathol., 138: 829, 1991
117. Storgard C.M., Stupack D.G., Jonczyk A., Goodman S.L., Fox R.I., Cheresh D.A., Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J. Clin. Invest., 103: 47, 1999
118. Skotnicki J.S., Zask A., Nelson F.C., Albright J.D., Levin, J.I., Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann. NY Acad. Sci. Jun., 30: 87861, 1999
119. Loetscher P., Dewald B., Baggiolini M., Seitz M., Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes: effects of anti-rheumatic drugs. Cytokine, 6: 162, 1994
120. Seitz M., Dewald B., Gerber N., Baggiolini M., Enhanced production of neutrophil-activating peptide-1/interleukin-8 in rheumatoid arthritis. J. Clin. Invest., 87: 463, 1991
121. Taylor P.C., Peters A.M., Paleolog E., Chapman P.T., Elliott M.J., McCloskey R., Feldmann M., Maini R.N., Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum., 43: 38, 2000
122. Gong J.H., Ratkay L.G., Waterfield J.D., Clark-Lewis I., An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J. Exp. Med., 186: 131, 1997